Nuformix Share Discussion Threads

[georgeo1] 22/3/2021 16:09

The agreement with Nuformix allows Oxilio to focus on developing rapidly a unique formulation and dosage form with NXP001 and progressing into the clinic.

[georgeo1] 22/3/2021 14:03

Were going global with this guy on board.

[georgeo1] 22/3/2021 14:03

Oxilio Director --Simon YaxleySimon obtained his doctorate in Neuroscience from Oxford University in 1985 and following several years in academic research, joined the pharmaceutical industry.?He is a drug development professional having extensive experience of working with major pharmaceutical, biotechnology, and medical device companies all over the world. He has worked across all phases of clinical product development and in a variety of therapeutic areas.?In 2002 he founded Premier Research, a clinical contract research organisation, which he grew to more than 1400 drug development professionals working out of offices in 26 countries. As CEO, he developed the business to focus on oncology, central nervous system disorders, and pain management clinical product development. He took the company public in 2004 and then private, with the help of private equity, in 2008. After becoming Deputy Chairman in 2009, Simon eventually left Premier Research to work as an adviser to a variety of different drug development organisations.

[georgeo1] 22/3/2021 14:01

https://www.oxilio.co.uk/about-us

[georgeo1] 22/3/2021 14:00

Our approach to drug repurposing sets us apart from most other repurposing companies.  We aim to repurpose an existing drug through optimisation of the formulation, dose and dosing regimen in order to maximise its efficacy in the new indication. Our OXL001 clinical trial programme is being designed to satisfy all aspects of drug safety and efficacy associated with optimal formulation, dose and dosing regimen of OXL001 in the treatment of cancer.  The programme is informed by our advanced formulation and modelling/simulation work. We aim to take our first formulation of OXL001 into the clinic later in 2021.From oxilio website.

[georgeo1] 22/3/2021 13:53

Or placing.

[georgeo1] 22/3/2021 13:52

It's on their march 10th rns .

[hollywood6] 22/3/2021 13:29

You can easily buy

[hollywood6] 22/3/2021 13:28

No it shouldn't.

[georgeo1] 22/3/2021 12:51

pursue additional business development opportunities for NXP001 in oncology should Oxilio not exercise the option to license NXP001 in oncology;This was one of the proposal for fund raising.

[jotoha2] 22/3/2021 11:49

Hammer head forming , great sign , lets make it a sledge hammer today.

[georgeo1] 22/3/2021 11:37

https://www.twuko.com/tag/NFX

[georgeo1] 22/3/2021 11:31

Enough from me for now.

[georgeo1] 22/3/2021 11:30

https://twitter.com/JimSpoons1/status/1373948559297548291?s=19

[georgeo1] 22/3/2021 11:29

https://twitter.com/JimSpoons1/status/1373955098951442432?s=19

[georgeo1] 22/3/2021 11:28

@JimSpoons1Twitter

[georgeo1] 22/3/2021 11:28

In reality #NFX should be a £40-50M MCap company not £14M as it currently is. That just puts it in line with it's peers.@JimSpoons1Twitter.

[georgeo1] 22/3/2021 11:26

#NFX buyers descending on what could be one of the most undervalued stocks in the market.

[georgeo1] 22/3/2021 11:24

Has oxilio already renamed NXP001 to OXL001

[georgeo1] 22/3/2021 11:00

Getting harder to buy now.

[georgeo1] 22/3/2021 10:51

https://www.stockmarketwire.com/article/7197730/Nuformix-welcomes-move-by-Oxillio-to-exercise-option-agreement.html

[georgeo1] 22/3/2021 10:41

I was trying to say that Merck product expired and nuformix NXP001 been improved and patent protected. Buyers...be ready for a better product.

[georgeo1] 22/3/2021 10:37

Probably wasn't the placing earlier. Placing is provisional and yet to be approved.

[georgeo1] 22/3/2021 10:35

NXP001 been improved and patent protected. Ready for licensing.